Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. The 30-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. The 30-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.1 for that window. We currently track 2 Biotech stories that mention AxoGen, published between February 21, 2026 and March 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 372 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AxoGen. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
AxoGen is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
